Currently, HHT is the only ribosome inhibitor specifically used for the treatment of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS)5. The gene discussed is ACVRL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.